Abstract:The demand for PET tracers that target prostate-specific membrane antigen (PSMA) continues to increase. Meeting this demand with approved 68 Ga- and 18 F-labeled PSMA tracers is challenging outside of major urban centers. This is because the short physical half-life of these radionuclides makes it necessary to produce them near their sites of usage. To overcome this challenge, we propose cyclotron-produced 61 Cu for labeling PSMA PET tracers. 61 Cu can be produced on a large scale, and its 3.33-h half-life allows shipping over considerably longer distances than possible for 68 Ga and 18 F. Production of true theranostic twins using 61 Cu and the β – -emitter 67 Cu is also feasible. Methods: PSMA-I&T (DOTAGA-(l-y)fk(sub-KuE)) and its derivative in which the DOTAGA chelator was replaced by NODAGA (NODAGA-(l-y)fk(sub-KuE)), herein reported as DOTAGA-PSMA-I&T and NODAGA-PSMA-I&T, respectively, were labeled with 61 Cu and compared with [ 68 Ga]Ga-DOTAGA-PSMA-I&T, [ 68 Ga]Ga-NODAGA-PSMA-I&T, [ 68 Ga]Ga-PSMA-11, and [ 18 F]PSMA-1007. In vitro (lipophilicity, affinity, cellular uptake, and distribution) and in vivo (PET/CT, biodistribution, and stability) studies were performed in LNCaP cells and xenografts. Human dosimetry estimates were calculated for [ 61 Cu]Cu-NODAGA-PSMA-I&T. First-in-human imaging with [ 61 Cu]Cu-NODAGA-PSMA-I&T was performed in a patient with metastatic prostate cancer. Results: [ 61 Cu]Cu-DOTAGA-PSMA-I&T and [ 61 Cu]Cu-NODAGA-PSMA-I&T were synthesized with radiochemical purity of more than 97%, at an apparent molar activity of 24 MBq/nmol, without purification after labeling. In vitro, natural Cu ( nat Cu)-DOTAGA-PSMA-I&T and nat Cu-NODAGA-PSMA-I&T showed high affinity for PSMA (inhibitory concentration of 50%, 11.2 ± 2.3 and 9.3 ± 1.8 nM, respectively), although lower than the reference nat Ga-PSMA-11 (inhibitory concentration of 50%, 2.4 ± 0.4 nM). Their cellular uptake and distribution were comparable to those of [ 68 Ga]Ga-PSMA-11. In vivo, [ 61 Cu]Cu-NODAGA-PSMA-I&T showed significantly lower uptake in nontargeted tissues than [ 61 Cu]Cu-DOTAGA-PSMA-I&T and higher tumor uptake (14.0 ± 5.0 percentage injected activity per gram of tissue [%IA/g]) than [ 61 Cu]Cu-DOTAGA-PSMA-I&T (6.06 ± 0.25 %IA/g, P = 0.0059), [ 68 Ga]Ga-PSMA-11 (10.2 ± 1.5 %IA/g, P = 0.0972), and [ 18 F]PSMA-1007 (9.70 ± 2.57 %IA/g, P = 0.080) at 1 h after injection. Tumor uptake was also higher for [ 61 Cu]Cu-NODAGA-PSMA-I&T at 4 h after injection (10.7 ± 3.3 %IA/g) than for [ 61 Cu]Cu-DOTAGA-PSMA-I&T (4.88 ± 0.63 %IA/g, P = 0.0014) and [ 18 F]PSMA-1007 (6.28 ± 2.19 %IA/g, P = 0.0145). Tumor-to-nontumor ratios of [ 61 Cu]Cu-NODAGA-PSMA-I&T were superior to those of [ 61 Cu]Cu-DOTAGA-PSMA-I&T and comparable to those of [ 68 Ga]Ga-PSMA-11 and [ 18 F]PSMA-1007 at 1 h after injection and increased significantly between 1 and 4 h after injection in most cases. Human dosimetry estimates for [ 61 Cu]Cu-NODAGA-PSMA-I&T were similar to the ones reported for 18 F-PSMA ligands. First-in-human imaging demonstrated multifocal osseous and hepatic metastases. Conclusion: [ 61 Cu]Cu-NODAGA-PSMA-I&T is a promising PSMA radiotracer that compares favorably with [ 68 Ga]Ga-PSMA-11 and [ 18 F]PSMA-1007, while allowing delayed imaging.

Synthesis and preclinical evaluation of 68 Ga-labeled PSMA tracers with improved pharmacological properties

Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties

Design, synthesis and evaluation of novel prostate-specific membrane antigen-targeted aryl [ 18 F]fluorosulfate PET tracers

Improve the Biodistribution with Bulky and Lipophilic Modification Strategies on Lys-Urea-Glu-Based PSMA-Targeting Radiotracers.

Design, Synthesis and Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Aryl [18f]fluorosulfate Pet Tracers

In vitro and in vivo comparative study of a novel 68 Ga-labeled PSMA-targeted inhibitor and 68 Ga-PSMA-11

In vitro and in vivo comparative study of a novel 68Ga-labeled PSMA-targeted inhibitor and 68Ga-PSMA-11

In Vitro and in Vivo Comparative Study of a Novel 68 Ga-Labeled PSMA-Targeted Inhibitor and 68 Ga -PSMA-11

In Vitro and in Vivo Comparative Study of 68Ga-Labeled DOTA-, NOTA-, and HBEDCC-chelated Radiotracers Targeting Prostate-Specific Membrane Antigen

Synthesis and Evaluation of 99mTc-Labeled DPro-Gly-Containing Tracers Targeting PSMA

Synthesis and Preclinical Evaluation of Two Novel 68Ga-Labeled Bispecific PSMA/FAP-Targeted Tracers with 2-Nal-Containing PSMA-Targeted Pharmacophore and Pyridine-Based FAP-Targeted Pharmacophore

Preclinical development of a novel [68Ga]Ga-/[177Lu]Lu-labeled agent for PSMA-targeted imaging and therapy

Synthesis and Characterization of a Novel 68Ga-Labeled P-Bromobenzyl Lysine-Urea-odap PSMA Inhibitor

Synthesis and Evaluation of 99m Tc-Labeled l-Aspartic Acid as a EuK Polymer Linker for Targeting PSMA to a Novel SPECT Tumor Tracer

64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer

Synthesis and Preclinical Evaluation of 68Ga-Psma-bch for Prostate Cancer Imaging.

One-Step 18F-Labeling and Preclinical Evaluation of Prostate-Specific Membrane Antigen Trifluoroborate Probes for Cancer Imaging

Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging

61Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging

Synthesis and Evaluation of F-18-Ambf3-Psma Derivatives As Pet Imaging Agents for Prostate Cancer

[68Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer